Dicot signs extended Service Agreement with Anthem Biosciences for Preclinical Development of Libiguin™
Dicot has signed an extended service agreement with Anthem Biosciences, Bangalore, India for preclinical developments of Libiguin™. Dicot has already since May 2017 collaborated with Anthem for development of chemical process steps for the production of Libiguin™. The new extended agreement includes both the toxicity tests required for regulatory approval of clinical trials of Libiguin™, and further optimizations of the chemical process steps for the manufacture of Libiguin™. The agreement assures Dicot the full intellectual property right of all developments by Anthem Biosciences regarding Libiguin™.
Anthem Biosciences is a Contract Research Organization with about 500 employees and a well-developed infrastructure that is highly suitable for the development phase Dicot is currently in. A significant part of Dicot's preclinical developments take place at Anthem.
- The work already done for Dicot's behalf at Anthem has been of high quality and very cost-effective," says Göran Beijer, CEO of Dicot AB, and continues:
- The capacity offered by Anthem now gives us the opportunity to effectively carry out a significant part of the preclinical development required for the approval of Libiguin™ for clinical trials.
For further information
Göran Beijer
CEO, Dicot AB
Telefon: +4670-663 60 09
E-post: [email protected]
About Dicot
Dicot develops drugs against sexual dysfunction with a large market potential. Dicot's most important product will be LibiguinTM for the treatment of erectile dysfunction and premature ejaculation.Preclinical development will be done in-house in front of entering clinical studies.Dicot will seek strategic alliances with global pharmaceutical companies to introduce Libiguin TM on the world market.
Filer
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
